Follow The Filings

ANRO Alto Neuroscience

Alto Neuroscience earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ANRO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ANRO insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $3.6M sold by 1 insider under 10b5-1 plans
  1. Nicholas Conrad Smith CFO
    Planned sale
    $3.6M 134,886 shares at $26.45 85% of stake
    Traded Sep 29–30 Filed Oct 1
    ↗

Also filed in the last 12 months, not counted as buying or selling: 4 option exercises, 2 share withholdings for taxes, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 2.02,8.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 1.01,3.02,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.